Dr. Alva on the Shift Toward Combination Therapy in mRCC


Ajjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.

Ajjai Shivaram Alva, MBBS, an associate professor at the University of Michigan, discusses the shift toward combination therapy in metastatic renal cell carcinoma (mRCC).

The role of combination therapy has grown significantly in mRCC, explains Alva. As such, the utility of monotherapy in this space is diminishing.

By combining TKIs and checkpoint inhibitors, patients get the benefit of dual VEGF and PD-1/PD-L1 blockade, says Alva. Historically, both classes of agents have demonstrated activity in mRCC.

Going forward, the question of what treatment to give patients who progress on a TKI/immunotherapy combination needs to be answered, Alva says.

Novel classes of agents including metabolic inhibitors, glutamine inhibitors, arginase inhibitors, and HIF-1α inhibitors may have a role in the second-line setting, concludes Alva.

Related Videos
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
© 2024 MJH Life Sciences

All rights reserved.